The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study

Table 2 Cross-sectional associations at baseline between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity

	Adjusted linear regression		Multivariate linear regression
	β coefficient	P value	β coefficient	P value
Age	1.02 (1.01–1.03)	< 0.001	1.009 (1.00–1.02)	0.04
Male gender	0.74 (0.59–0.95)	0.02	0.10 (0.04–0.23)	< 0.001
C-reactive protein^a	1.01 (1.01–1.02)	0.002	1.01 (1.01–1.02)	0.001
RF IgM-positive^{a, b}	0.96 (0.79–1.17)	0.67
Anti-CCP-positive^{a, b}	0.90 (0.74–1.10)	0.30
Gluocorticoid user^{a, b}	1.17 (0.94–1.48)	0.16
DMARD user^{a, b}	1.04 (0.85–1.26)	0.71
NSAID user^{a, b}	0.97 (0.80–1.19)	0.81
Ritchie score^a	1.01 (0.99–1.03)	0.21
HAQ^a	1.06 (0.90–1.24)	0.47
Sharp score^a	1.00 (0.99–1.02)	0.93
Disease duration^a	0.99 (0.91–1.08)	0.82
Age × male gender			1.04 (1.02–1.05)	< 0.001
R² adjusted			0.23	< 0.05

^aAge- and gender-adjusted; ^bdichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.

ISSN: 1478-6362